Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Insight & Intelligence™

Back to Item »

Dendreon’s $70M Investment in Production Capabilities Could Woo Firms without Similar Expertise

If cell-based immune therapy Provenge receives FDA sanction, it may corner a large market share and expand the company’s prospects.

Forward this item to a colleague:
Your name
Your email
(Separate multiple addresses by commas)
 
Colleague's email
(Separate multiple addresses by commas)
 
Personal Message
(optional)
 
 
 

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll